Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493171 | 0.84 | KDM4E (0.34) | APPLMNAKDM4EGLAGAA | |
| SCHEMBL1375733 | 0.82 | CYP1A2 (0.45) | LMNAKDM4EGLAGAACYP1A2 | |
| SCHEMBL5971805 | 0.82 | L3MBTL1 (0.37) | LMNAKDM4EGLAGAAALDH1A1 | |
| SCHEMBL12151159 | 0.80 | KDM4E (0.38) | KDM4EGLAGAACYP1A2CYP2C19 | |
| SCHEMBL5972348 | 0.79 | IMPDH2 (0.49) | IMPDH2IMPDH1 | |
| SCHEMBL27985408 | 0.72 | LMNA (0.45) | LMNAKDM4EGAACYP1A2CYP2C19 | |
| SCHEMBL14064554 | 0.72 | CYP3A4 (0.45) | HPGDCA12CA1CA2CA7 | |
| SCHEMBL9041942 | 0.72 | CYP3A4 (0.41) | LMNAKDM4EGAAALDH1A1HPGD | |
| SCHEMBL29116936 | 0.71 | POLB (0.38) | LMNAKDM4EGAAALDH1A1HPGD | |
| SCHEMBL31643783 | 0.70 | LMNA (0.41) | APPLMNAKDM4ECYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1620110-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1617848-A2 | ANTI-CANCER PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050256078-A1 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | GILEAD SCIENCES, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004096286-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096287-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096236-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | PHOSPHO1, NFATC1, IFNG | APP 2097/4885LMNA 4759/4885KDM4E 3404/4885 |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | APP 3641/4885LMNA 2918/4885KDM4E 2471/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | APP 3641/4885LMNA 2918/4885KDM4E 2471/4885 |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | APP 3641/4885LMNA 2918/4885KDM4E 2471/4885 |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | EIF2AK2, PNP, NUDT1 | APP 4317/4885LMNA 2901/4885KDM4E 2597/4885 |
| US-20050256078-A1 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | IMPDH1, IMPDH2, ITPA | APP 3314/4885LMNA 2317/4885KDM4E 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.